ATRX.US Adhera Therapeutics Inc

Healthcare Biotechnology USA Stocks
0.0001 USD
Close of Nov 13, 2026
0.0001 0.0001
Market cap
USD 722.00
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Is ATRX.US undervalued?

Graham number

The Graham number of Adhera Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Adhera Therapeutics Inc fundamental analysis

No fundamental analysis for Adhera Therapeutics Inc yet.

Adhera Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Adhera Therapeutics Inc

Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing MLR-1019 for the treatment of Parkinson's disease; and MLR -1023 to treat Type 1 diabetes. The company was formerly known as Marina Biotech, Inc. and changed its name to Adhera Therapeutics, Inc. in October 2018. Adhera Therapeutics, Inc. is based in Baton Rouge, Louisiana.

Full company profile